SCHEMBL19570

SCHEMBL19570

CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(CO)CC[C@]3(C)CC[C@]12C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.74
CCR6 P51684 1/20 0.74
PAX8 Q06710 1/20 0.74
TLR9 Q9NR96 1/20 0.74
NR4A1 P22736 7/20 0.73
TERT O14746 6/20 0.72
PTPN1 P18031 1/20 0.71
CASP1 P29466 1/20 0.71
ABHD6 Q9BV23 1/20 0.71
KDM4E B2RXH2 1/20 0.71
TP53 P04637 1/20 0.71
CYP3A4 P08684 1/20 0.71
MAPT P10636 1/20 0.71
HPGD P15428 1/20 0.71
ALOX15 P16050 1/20 0.71
ALOX12 P18054 1/20 0.71
MAPK1 P28482 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
TDP1 Q9NUW8 1/20 0.71
HSP90AB1 P08238 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17124742 0.93 NR4A1 (0.75) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL20780 0.92 HSP90AA1 (0.73) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL18781875 0.91 NR4A1 (0.73) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL20433 0.90 TERT (0.72) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL18781834 0.88 NR4A1 (0.69) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL20988498 0.88 NR4A1 (0.77) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL17328976 0.88 HSP90AA1 (0.73) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL18781870 0.88 NR4A1 (0.72) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL18781832 0.88 HSP90AA1 (0.79) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL17328989 0.88 HSP90AA1 (0.79) HSP90AA1CCR6PAX8TLR9NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609108-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS SUZHOU NEUPHARMA CO LTD (CN) 2015-12-16 EP claimed
US-20120052019-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2012-03-01 US claimed
US-11753436-B2 Analogs of celastrol ERX PHARMACEUTICALS CORPORATION (US) 2023-09-12 US disclosed
US-11753436-B2 Analogs of celastrol ERX PHARMACEUTICALS CORPORATION (US) 2023-09-12 US disclosed
US-20210061851-A1 ANALOGS OF CELASTROL ERX PHARMACEUTICALS CORPORATION 2021-03-04 US disclosed
US-10662218-B2 Analogs of celastrol ERX PHARMACEUTICALS CORPORATION 2020-05-26 US disclosed
US-20180194709-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION 2018-07-12 US disclosed
US-20180194709-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION 2018-07-12 US disclosed
WO-2017070615-A1 ANALOGS OF CELASTROL ERX PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
EP-2609108-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS SUZHOU NEUPHARMA CO LTD (CN) 2015-12-16 EP disclosed
EP-2609108-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS SUZHOU NEUPHARMA CO LTD (CN) 2015-12-16 EP disclosed
WO-2015148802-A1 CELASTROL AND DERIVATIVES FOR THE TREATMENT OF OBESITY THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2015-10-01 WO disclosed
US-20150274634-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION 2015-10-01 US disclosed
US-20150274634-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION 2015-10-01 US disclosed
US-20120052019-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2012-03-01 US disclosed
US-20120052019-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2012-03-01 US disclosed
US-20120052019-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2012-03-01 US disclosed
WO-2012024893-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS SUZHOU NEUPHARMA CO., LTD. (CN) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061851-A1 ANALOGS OF CELASTROL GIPR, GPR119, EBP HSP90AA1 123/4885CCR6 3242/4885PAX8 965/4885
US-20180194709-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF GPR119, FABP4, ADIPOR1 HSP90AA1 2473/4885CCR6 674/4885PAX8 3588/4885
US-20150274634-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF GPR119, FABP4, ADIPOR1 HSP90AA1 2473/4885CCR6 674/4885PAX8 3588/4885
US-20120052019-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS LTB4R2, PTGER4, PMP22 HSP90AA1 3632/4885CCR6 474/4885PAX8 1959/4885
US-10662218-B2 Analogs of celastrol GIPR, GPR119, EBP HSP90AA1 123/4885CCR6 3242/4885PAX8 965/4885
US-11753436-B2 Analogs of celastrol GIPR, GPR119, EBP HSP90AA1 123/4885CCR6 3242/4885PAX8 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.